Treatment-free remission (TFR) after discontinuation of tyrosine kinase inhibitor therapy is now an emerging treatment goal for patients with chronic myeloid leukemia, who have achieved a deep and stable response to treatment. Although guidance is now available, patients' questions regarding this progressive concept have yet to be addressed. The overall aim of this European Steering Group is a patient-centered approach that educates patients on their treatment options, including TFR, facilitates better patientephysician relationships, and meets patients' emotional and psychological needs. The present report outlines 5 key topic areas on discontinuing tyrosine kinase therapy and the implications of TFR for patientephysician consideration: what TFR is; when TFR is appropriate; which patients might and might not be eligible for TFR; and patients' considerations for discontinuing therapy, such as tyrosine kinase withdrawal syndrome, potential psychological implications, molecular recurrence, and repeat treatment. This Steering Group advocates that patients with chronic myeloid leukemia should have access to high-quality, frequent molecular monitoring and be treated in a specialist center with appropriate medical and psychological support. As patient concerns with attempting TFR become forefront in patientephysician discussions, a greater number of eligible patients might be willing to discontinue therapy.
Introduction
The introduction of tyrosine kinase inhibitors (TKIs) has considerably improved the outcomes for patients with chronic myeloid leukemia (CML), with survival rates now almost equal to that of the healthy, general population. Although the incidence of this rare disease remains at w1 case per 100,000 population, 1 improved survival has resulted in an increased prevalence, and 400,000 patients with CML are expected in Europe by 2050. 2 With the better survival and increasing prevalence of CML comes a different set of challenges for patients and physicians, including the side effects of continuous treatment on a patient's health, wellbeing, and quality of life (QoL) and the increasing health care burden and costs associated with managing a lifelong disease. 2 The concept of discontinuing TKI therapy for certain patients, an approach first put forward in 2006, 3 has the potential to reduce side effects associated with lifelong TKI therapy and to be a cost-effective measure for health care providers. 2 Although discontinuation of TKI therapy is still largely conducted in controlled clinical trials, and standard protocols for TKI discontinuation in clinical practice have not yet been developed, guidelines and recommendations are available for eligible patients considering TKI withdrawal and attempting treatment-free remission (TFR). 2, [4] [5] [6] [7] This guidance considers both patient selection criteria and the eligibility of centers to adequately monitor patients with standardized and timely molecular testing of BCR-ABL1 transcripts. 4, 6, 8 TFR after discontinuation of TKI therapy is an emerging treatment goal for patients who have had a deep and stable response to treatment. For the purposes of the present report, TFR can be described as a state in which a patient with CML has discontinued TKI therapy and remained in major molecular response (MMR; also known as MR3.0, or a level of 0.1% on the international scale), thereby remaining free of the need for TKI therapy. Although recent 2017 guidelines on patient eligibility for discontinuing TKIs and attempting TFR are available from the National Comprehensive Cancer Network (NCCN) and the European Society for Medical Oncology (ESMO), 4, 8 with the European LeukemiaNet guidelines available in early 2018, 6 patients' concerns and questions regarding this progressive concept have yet to be addressed in reported studies.
With the patients' perspective in mind, a European Steering Group of 6 health care professionals (specialist hematologists) and 6 experienced CML patient advocates (some with a personal experience of TFR) convened in July 2017 in Vienna to discuss key areas and patient concerns relating to discontinuing TKI therapy for patients with CML. The overall aim of this Steering Group, founded in July 2016 from members of the CML Advocates Network (an international network connecting 116 patient organizations from 86 countries advocating the sharing of best TFR is achieved when a patient who has discontinued TKI therapy maintains MMR and does not need to restart therapy; patients in the chronic phase of CML with a stable, prolonged, and DMR for 2 years might be ready to discontinue TKI therapy and attempt TFR. Which patients might be eligible to attempt TFR?
The following factors should be considered before attempting TFR: patients in the chronic phase of CML at diagnosis, who have not experienced resistance to any TKI therapy at any time, and who have been in DMR for 2 years; patients should be well-informed about TFR and well-motivated to discontinue treatment but not experiencing pressure to stop therapy 4, 7 ; patients should fully understand that molecular recurrence is not "failure" and that treatment will be restarted; molecular monitoring test results should be available within 2-4 weeks. 4, 7 Which patients might not be eligible to attempt TFR? Patients who have achieved MMR/MR3.0 but have not reached a DMR and are, therefore, not eligible to attempt TFR should be reassured by their physicians that they have still reached a treatment goal/safe haven and can continue TKI treatment and have a life expectancy similar to that the general population. If these patients continue to adhere to treatment, they can continue with the same therapy and wait to reach a deeper molecular response, at which time, once sustained, TFR might be an option. If a patient wishes to stop treatment and has a specific desire or need to change therapy, the physician should discuss with the patient the possibility of switching to a second-generation TKI that might enable achievement of a deeper molecular response; these patients should also be advised about the different side effect profiles of TKI treatments. Patient considerations for discontinuing TKI therapy
The following factors should be considered before a patient discontinues TKI therapy: physicians should emphasize the importance and frequency of follow-up visits and, therefore, the commitment necessary from patients to attend clinic visits more frequently; TFR does not mean a cure, and molecular recurrence can develop at any time, requiring TKI treatment to be restarted; even if TFR is achieved, physicians should remind patients that they will still need to attend routine clinic visits and undergo regular, lifelong monitoring. TKI withdrawal syndrome Physicians should discuss TKI withdrawal syndrome with patients considering discontinuing TKI therapy and how the syndrome can be managed; on withdrawal of TKI treatment, some patients might experience musculoskeletal pain, which, generally, can be managed with over-the-counter pain medications. In addition to ongoing disease surveillance, regular clinical monitoring will enable the identification of long-term toxicity of previous TKI therapy or, even, of its discontinuation; withdrawal symptoms should be monitored and treated. Psychological implications of discontinuing TKI therapy and attempting TFR Current guidelines do not address the psychological issues related to discontinuing TKI therapy and attempting TFR. However, Steering Group members advocate that screening for potential psychological issues associated with TFR should form a part of routine monitoring for patients, because professional psychological help might be necessary for certain patients. Physicians should also be aware that patients could experience anxiety as a result of fluctuating blood levels of BCR-ABL1 during TRF monitoring.
Molecular recurrence and retreatment
Patients should be prepared for drug-free periods that could last from only a few months to many years, and physicians should explain and advise patients about the possibility of reinitiation of therapy owing to molecular recurrence.
Abbreviations: CML ¼ chronic myeloid leukemia; DMR ¼ deep molecular response; MMR ¼ major molecular response; OS ¼ overall survival; QoL ¼ quality of life; TFR ¼ treatment-free remission; TKI ¼ tyrosine kinase inhibitor.
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Joint PatientePhysician Perspectives on TFR in CML practice in CML), is for a patient-centered approach that addresses the unmet needs of patients with CML. The group's main objectives include educating patients on their treatment options, including with respect to TFR; facilitating better patientephysician relationships using patient empowerment as a method to improve CML care; and meeting patient needs (including emotional and psychological needs) within the CML community. The present report outlines 5 key topic areas or questions about discontinuing TKI therapy and the implications of TFR for patientephysician consideration (Table 1 ). In view of recent guidelines, this collective narrative also provides timely discussion points from an experienced Steering Group of specialist hematologists and CML patient advocates, offering a unique, joint patientephysician perspective that compliments current guidance and reported data. For accessibility of the information provided in the present report, a glossary of terms has been provided ( Table 2) .
What Is TFR and When Is TFR Appropriate?
TFR is achieved when a patient who has discontinued TKI therapy maintains a MMR and does not need to restart therapy. The Steering Group members agreed that, in general, patients in the chronic phase of CML with a stable, prolonged, and deep molecular response (DMR) for 2 years might be ready to discontinue TKI therapy and attempt TFR.
For patients participating in controlled clinical trials, the achievement of DMR can be defined as BCReABL1 transcripts present at 0.01% (ie, an MR4.0-, MR4.5-, or MR5.0-log reduction from the standardized baseline [MR4.0 or deeper]). 8 In the largest TFR trial to date (European Stop TKI [EURO-SKI] study), achievement of MR4.0 was sufficient for TFR eligibility for many patients. 9 However, the eligibility for the recent ENEST freedom study was based on the more stringent criterion of MR4.5 (BCReABL1 transcript levels of 0.0032%).
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Analysis of the EURO-SKI data suggested that responses deeper than MR4 provide no advantage in terms of long-term TFR 9 ;
however, this finding has yet to be confirmed by ongoing trials, such as the ENESTPath trial (ClinicalTrials.gov identifier, NCT01743989).
Currently, the ESMO and NCCN guidelines recommend attempting TFR outside of clinical trials, as long as proper, highquality, well-regulated, and certified monitoring can be ensured. 4, 8 The 2017 ESMO guidelines recommend that before discontinuing therapy, patients should have achieved MR4.5 and stability of the DMR (at least MR4.0) for 2 years after 5 years of TKI therapy. 8 The NCCN guidelines state that TFR can be attempted for carefully selected patients who have achieved and maintained a DMR (MR4.0 or deeper) for 2 years. 4 After achievement of a stable DMR, TFR should be seen by the CML community as an option in CML treatment. It should not be thought of as a cure for CML, because molecular recurrence, both early and occasionally late, does develop in some patients.
Which Patients Might Be Eligible to Attempt TFR?
Members of the Steering Group agreed that the following factors should be considered when a patient is considering a TFR attempt. Patients should have been in the chronic phase of CML at diagnosis, should not have experienced resistance to any TKI therapy at any time, should have had a DMR for 2 years. Patients also need to be well-informed about TFR and well-motivated to discontinue treatment but should not experience pressure to stop therapy. 4, 7 Patients should also fully understand that molecular recurrence is not a "failure," and that treatment will be restarted if it develops. Molecular monitoring test results should also be available within 2 to 4 weeks. 4, 7 A longer duration of TKI therapy before attempting TFR has been associated with a greater chance of sustaining a MMR. [9] [10] [11] Overall, for first-line TKIs, 31% of patients will be eligible for TFR at 6 years. 12 
Which Patients Might Not Be Eligible to Attempt TFR?
The Steering Group acknowledged that patients who have achieved a MMR/MR3.0 but have not reached a DMR and are therefore not eligible to attempt TFR should be reassured by their physicians that they have still reached a treatment goal or safe haven and can continue receiving TKI treatment and have a similar life expectancy to that of the general population. If these patients continue to adhere to treatment they can continue with the same therapy and wait to reach a deeper molecular response, at which point, once sustained, TFR might be an option. If a patient wishes to stop treatment and has a specific desire or need to change therapy, the physician should discuss with the patient the possibility of switching to a second-generation TKI that might enable achievement of a deeper molecular response. At this time, patients should be advised about the side effect profiles of TKI treatments. The recommendations provided by the Steering Group are supported by the reported data. Patients who have achieved a MMR/MR3.0 have a minimal risk of disease progression and have a life expectancy similar to that of the general population as long as they continue to adhere to their TKI therapy. 13, 14 Patients who have not achieved a MR3.0 with their current therapy can be switched to a different TKI if necessary. This could increase their chances of attaining a DMR. Patients are more likely to achieve both a DMR with second-generation TKIs and achieve this more quickly than with first-generation TKIs. However, adherence to therapy is a critical factor in achieving a DMR. 8 
Patient Considerations for Discontinuing TKI Therapy
The Steering Group recommends that physicians discuss the following points with patients considering discontinuing TKI therapy. Before discontinuing TKI therapy, the importance and frequency of the follow-up visits and, therefore, the commitment by patients to attend clinic appointments more frequently should be emphasized. TFR does not mean a cure, and molecular recurrence can develop at any time, requiring TKI treatment to be restarted. Even if TFR has been achieved, physicians should remind patients that they will still need to attend routine clinic visits and undergo regular and lifelong monitoring.
TKI Withdrawal Syndrome
The Steering Group strongly recommends that physicians discuss TKI withdrawal syndrome with patients thinking about discontinuing TKI therapy and how the syndrome can be managed. On withdrawal of TKI treatment, some patients might experience musculosketal pain. Generally, the pain can be managed with overthe-counter pain medications. In addition to ongoing disease surveillance, clinical monitoring will enable the identification of long-term toxicity of previous TKI therapy or, even, of its discontinuation. All withdrawal symptoms should be monitored and treated.
Study data have suggested that 30% of patients who stop TKI therapy will experience the withdrawal syndrome, usually in the form of musculoskeletal pain. [15] [16] [17] Although TKI withdrawal syndrome can last for months, it can often be managed with nonprescription drugs such as paracetamol or nonsteroidal anti-inflammatory drugs, and, in more severe cases, corticosteroids. 16, 17 The TKI withdrawal syndrome does not appear to be dependent on the particular TKI the patient was taking before stopping therapy, 17 and the occurrence of the TKI withdrawal syndrome has been associated with a greater chance of achieving successful TFR. 10 Psychological Implications of Discontinuing TKI Therapy and Attempting TFR
The current guidelines have not addressed the psychological issues related to discontinuing TKI therapy and attempting TFR. However, the Steering Group members advocate that screening for potential psychological issues associated with TFR should form a part of routine monitoring for patients, because professional psychological help might be necessary for certain patients. Physicians should also be aware that patients could experience anxiety as a result of fluctuating BCR-ABL1 blood levels during TFR.
It is well-recognized that psychological and emotional factors, in addition to clinical variables, play a vital part of a patient's decision to discontinue TKI therapy. Thus, these factors should be considered when discussing TFR with patients. 18 The main reasons for patients wanting to discontinue TKIs are to reduce the potential side effects of long-term TKI therapy, decrease medication costs, and ease the inconvenience of taking daily medication. 19, 20 The main anxiety that patients have experienced regarding stopping TKI therapy is a fear of disease recurrence or progression 18, 19 ; however, to date, this has not been documented. 2, 7 A recent Italian observational study found that about 82% of patients would be willing to stop TKI therapy if their disease were likely to remain stable and the probability of a response to TKI therapy if treatment needed to be restarted were high. Patients were also more likely to attempt TFR if their risk of recurrence was < 30%. 18 In addition, not all patients who are eligible for TFR will be willing to discontinue treatment. In a recent survey, 49% of Italian patients with CML (total, n ¼ 1133) and 34% of US patients with CML (total, n ¼ 84) would not choose to discontinue treatment owing to concerns of disease recurrence. 19, 20 Although patients and their physicians should discuss all concerns, including psychological and emotional concerns, of attempting TFR, it is recognized that, currently, these do not form a part of a routine clinic visit. 20 
Molecular Recurrence and Retreatment
The Steering Group highlighted that patients should be prepared for drug-free periods that could last from only a few months to many years and recommended that physicians advise patients about the possibility of reinitiation of therapy because of molecular recurrence.
Data have shown that not all patients eligible for TFR will sustain a response once TKI therapy has been discontinued: 40% to 60% of eligible patients will have a sustained TFR > 1 to 2 years. 4, 5, 7, 10, 11, 21 Most cases of molecular recurrence will develop within the first 6 months of stopping TKI therapy, 11 and the confirmed loss of MR3.0 should be seen as an indication to restart therapy. 22 Late molecular recurrences do develop; thus, patient adherence to monitoring during TFR is vital to detect recurrence and ensure protection from disease progression. 8, 11 Factors that are potentially predictive of molecular recurrence include previous TKI treatment duration and previous duration of DMR. 2 Joint PatientePhysician Perspectives on TFR in CML date, has been found of developing resistance to TKIs, 5, 10, 11, 21 and attempting a second TKI discontinuation after molecular recurrence is possible, once a prolonged DMR has again been achieved. Some data have shown this might be effective in w30% of cases after an adequate duration of the re-achieved DMR. The speed of molecular recurrence after the first attempt at TFR was the only factor associated with a poorer outcome with the second attempt. 23 
Conclusion
This Steering Group considered the patients' perspective, a potentially overlooked area of CML management. 2 This innovative approach, facilitating collaboration between specialist hematologists and CML patient advocates, highlights the practical considerations for eligible patients attempting TFR and advocates that patients with CML should have access to high-quality and frequent molecular monitoring and be treated in a specialist center with appropriate medical and psychological support. Despite the current uncertainties regarding which patients are the best candidates to attempt TFR and which factors will predict for the loss of MMR/ MR3.0 after discontinuing TKI therapy, treatment interruption is a safe option, providing adequate high-quality and timely monitoring is available, with prompt reintroduction of TKI therapy once MMR/MR3.0 has been lost. Worldwide, > 2000 patients with CML have attempted TFR, and no instances of disease progression have been reported. It is possible that as attempting TFR becomes a standard part of CML care, and patients' concerns are forefront to patientephysician discussions, a greater number of eligible patients will be willing to discontinue TKI therapy and attempt TFR.
